Three (50%) out of 6 SLE patients with the negative anti-GPIIb/IIIa ELISPOT result were positive for the anti-GPIb ELISPOT assay, but none of the patients with liver cirrhosis or post-HSCT who showed the negative anti-GPIIb/IIIa ELISPOT result were positive for the anti-GPIb ELISPOT assay. This evidence concerns the gene ITGA2B and cirrhosis of liver.